ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

Core Points - ARS Pharmaceuticals, Inc. will host a conference call on March 20, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results and business highlights [1] - The company is dedicated to empowering at-risk patients and caregivers to protect against allergic reactions that could lead to anaphylaxis [3] Company Information - ARS Pharmaceuticals is commercializing neffy® 2 mg (trade name EURneffy® in the EU), an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30 kg or greater [3] - The product is indicated for emergency treatment of allergic reactions due to insect stings or bites, foods, medicinal products, and other allergens, as well as idiopathic or exercise-induced anaphylaxis in both adults and children [3] Upcoming Events - ARS Pharma Management will participate in several investor conferences, including a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2025, and investor meetings at the 37th Annual Roth Conference from March 16-18, 2025 [4]